Table Graph
      published meta-analysis   sensitivity analysis   studies

metformin in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsCOVID-OUT (metformin), 2022 0.58 [0.35; 0.95] TOGETHER, 0 1.15 [0.66; 1.99] 0.81[0.41; 1.57]COVID-OUT (metformin), 2022, TOGETHER, 0269%1,730lownot evaluable hospitalization or deathdetailed resultsCOVID-OUT (metformin), 2022 0.47 [0.20; 1.11] 0.47[0.20; 1.11]COVID-OUT (metformin), 202210%1,307NAnot evaluable clinical deteriorationdetailed resultsCOVID-OUT (metformin), 2022 0.84 [0.65; 1.08] TOGETHER, 0 1.15 [0.66; 1.99] 0.89[0.70; 1.12]COVID-OUT (metformin), 2022, TOGETHER, 021%1,728moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-27 11:41 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 699 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons